Valve and Structural Heart Disease
Sanger has earned an international reputation as a leader in treating complex structural heart and valve conditions, and we’re home to some of the world’s top experts in minimally invasive procedures including TAVR and mitral TEER.
Recent Highlights
Increasing TAVR and mitral TEER volumes: Our team now performs more TAVR and mitral TEER procedures than any other center in the Carolinas, and we’re the most experienced center for tricuspid intervention.
Making LAAO available to more patients: We offer LAAO at Atrium Health Cabarrus and plan to extend this to Atrium Health Pineville, enabling more patients in our region to benefit from this procedure, closer to their homes.
Innovations
We’re often the first center in our region to make new investigational devices and interventions available to patients. We offer:
Evoque TTVR: Sanger is the first and only center in the Carolinas providing transcatheter tricuspid valve replacement. This complements our transcatheter tricuspid valve edgeto-edge repair trial, which led to a publication in the New England Journal of Medicine.
Cephea TMVR: We were one of the first five centers in the world to implant this fully transeptal delivered transcatheter mitral valve. This complements our nationallyrecognized Transcatheter Mitral Valve Program, which has nearly 20 years of experience, and the region’s highest volumes and best outcomes.
Short Cut: We’re the region’s only center offering this investigational device from PiCardia. The device splits bioprosthetic valve leaflets to reduce the risk of coronary obstruction with “valve-in-valve” therapy in patients with failed bioprosthetic valves.
Awards
TAVR
-
422
TAVR Procedures
Volume from Atrium Health Carolinas Medical Center and Atrium Health Cabarrus
Internal Data, YTD August 2023 Annualized
-
80
Mitral and Tricuspid Valve
Procedures
Internal Data, YTD August 2023 Annualized -
>90.0%
Mitral Valve Acute Procedural
Success - MR grade ≤ 2+
TVT Registry, September 2022 - August 2023 -
99%
Normal Valve Function
at 1-Year
Post Implantation
TVT Registry, September 2022 - August 2023 -
0.0%
Mitral Valve In-Hospital Mortality Rate Unadjusted Post Implantation
Benchmarks:
50th Percentile: 0.0%
90th Percentile: 0.0%
TVT Registry, September 2022 - August 2023 -
98%
LAAO Successful Closure on Follow-Up Imaging
LAAO Registry, September 2022 - August 2023
Structural Heart and Valve
Stone GW, Abraham WT, Lindenfeld J, et al. Five-Year Follow-up after Transcatheter Repair of Secondary Mitral Regurgitation. N Engl J Med. 2023;388(22):2037-2048. doi:10.1056/NEJMoa2300213. PMID: 36876756
Rogers JH, Asch F, Sorajja P, et al. Expanding the Spectrum of TEER Suitability: Evidence From the EXPAND G4 Post Approval Study. JACC Cardiovasc Interv. 2023;16(12):1474-1485. doi:10.1016/j. jcin.2023.05.014. PMID: 37380229
Shahim B, Redfors B, Stuckey TD, et al. On‐Treatment Platelet Reactivity and Ischemic Outcomes in Patients With Diabetes Mellitus: Two‐Year Results From ADAPT‐DES. Journal of the American Heart Association. 2023;12(1). doi:https://doi. org/10.1161/jaha.122.026482
McCarthy PM, Whisenant B, Asgar AW, et al. Percutaneous MitraClip Device or Surgical Mitral Valve Repair in Patients With Primary Mitral Regurgitation Who Are Candidates for Surgery: Design and Rationale of the REPAIR MR Trial. J Am Heart Assoc. 2023;12(4):e027504. doi:10.1161/JAHA.122.027504. PMID: 36752231
Spargias K, Lim DS, Makkar R, et al. Threeyear outcomes for transcatheter repair in patients with mitral regurgitation from the CLASP study. Catheter Cardiovasc Interv. 2023;102(1):145-154. doi:10.1002/ ccd.30686. PMID: 37178388 von Bardeleben RS, Rogers JH, Mahoney P, et al. Real-World Outcomes of FourthGeneration Mitral Transcatheter Repair: 30-Day Results From EXPAND G4. JACC Cardiovasc Interv. 2023;16(12):1463- 1473. doi:10.1016/j.jcin.2023.05.013. PMID: 37380228
Sorajja P, Whisenant B, Hamid N, et al. Transcatheter Repair for Patients with Tricuspid Regurgitation. N Engl J Med. 2023;388(20):1833-1842. doi:10.1056/ NEJMoa2300525. PMID: 36876753
K. Johnson ACS, RDCS, FASE, RCP, RRT, A. White RDCS, L. Hammond RDCS. S. Lubowicki RDCS. C. Frye RDCS, FASE, R. Musialowski MD, A. Kott MD, FASE. A case of valve sparing destructive endocarditis. Poster at ASE Scientific Sessions. June 2023.
Ross L, Ohrenstein O, Rama-Krishnan A, Rinaldi MJ, Skipper E, Hill T, Schwartz J, Frederick JR, Shah C, Downey W. Equity Opportunities in the Severe Aortic Stenosis Care Pathway. American College of Cardiology; March 6, 2023. Ali Ghandour MD; M. Ramzi Almajed MD; Ayman Alsaadi MD; Jeffrey Geske
MD; Federico Asch MD; Mithun Devraj MD; Erica Scherer BS; Carl Wilson MS; Markus Scherer MD; William O’Neill MD; Dee Dee Wang MD. Interventional Imaging Physician Operator Experience in Performance of Interventional TEE for TEER versus Standard of Care TEE: Multi-center Analysis. Oral Presentation at CSI Frankfurt 2023
Mohamed Ramzi Almajed MD; Ayman Alsaadi MD; Ali Hussein Ghandour MD; Jeffrey Geske MD; Federico Asch MD; Mithun Devraj MD; Erica Scherer BS; Carl Wilson MS; Markus Scherer MD; William W O’Neill MD; Dee Dee Wang MD. Overtime: A Multi-Center Analysis of Interventional TEE Procedure Times to Guide TEER Versus Standard of Care TEE. Poster Abstract at TVT Phoenix 2023
Leadership
-
Michael Rinaldi, MD
Co-Director, Structural Heart Program
-
Eric Skipper, MD
Co-Director, Structural Heart Program